The ratings of five Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Protalix BioTherapeutics (AMEX:PLX) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. Protalix BioTherapeutics is a biotechnology company that has developed plant cell culture technology and a bioreactor system. In Portfolio Grader’s specific subcategories of Earnings Revisions and Equity, PLX also gets F’s. For a full analysis of PLX stock, visit Portfolio Grader.
MannKind (NASDAQ:MNKD) earns a D this week, moving down from last week’s grade of C. MannKind is a biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The stock also gets an F in Cash Flow. The stock price has fallen 36.8% over the past month, worse than the 6% decrease the Nasdaq has seen over the same period of time. As of Oct. 24, 2012, 14.8% of outstanding MannKind shares were held short. For more information, get Portfolio Grader’s complete analysis of MNKD stock.
This is a rough week for Halozyme Therapeutics (NASDAQ:HALO). The company’s rating falls to D from the previous week’s C. Halozyme Therapeutics is a biopharmaceutical company developing products for the diabetes, cancer, dermatology and drug delivery markets. The stock receives F’s in Earnings Growth, Earnings Momentum, Equity, and Sales Growth. Wall Street appears to agree with the stock downgrade, with share prices dropping 29.5% over the past month.
To get an in-depth look at HALO, get Portfolio Grader’s complete analysis of HALO stock.
Raptor Pharmaceutical (NASDAQ:RPTP) earns a D this week, falling from last week’s grade of C. Raptor Pharmaceutical researches existing drugs to improve them through specialized drug targeting methods and formulation changes. The stock gets F’s in Equity and Cash Flow. Investors seem to agree with the downgrade and have pushed down the share price 15.8% over the past month. As of Oct. 24, 2012, 11.6% of outstanding Raptor Pharmaceutical shares were held short. For a full analysis of RPTP stock, visit Portfolio Grader.
Opko Health (NYSE:OPK) earns a F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). OPKO Health is involved in the discovery, development, and commercialization of pharmaceutical products, vaccines, and diagnostic products. The stock also gets an F in Equity. As of Oct. 24, 2012, 10.5% of outstanding Opko Health shares were held short. To get an in-depth look at OPK, get Portfolio Grader’s complete analysis of OPK stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
